Could aging human skin use a connective tissue growth factor boost to increase collagen content

Journal of Investigative Dermatology

Volumn 130, Issue 2, 2010, Pages 338-341

  Oliver, Noelynn ^a   Sternlicht, Mark ^a   Gerritsen, Karin ^b   Goldschmeding, Roel ^a,b  

^a FIBROGEN INC   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; PROCOLLAGEN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

AGING; COLLAGEN SYNTHESIS; HUMAN; NONHUMAN; NOTE; OSSIFICATION; PRIORITY JOURNAL; SKIN FIBROBLAST;

EID: 75649083149     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.331     Document Type: Note

References (17)

1. Abraham D (2008) Connective tissue growth factor: growth factor, matricellular organizer, fibrotic biomarker or molecular target for anti-fibrotic therapy in SSc? Rheumatology 47(Suppl 5):18-19
2. Abreu JG, Ketpura NI, Reversade B et al. (2002) Connective-tissue growth factor (CTGF) modulates cell signaling by BMP and TGF-β. Nat Cell Biol 4:599-604
3. Chen Y, Segarini P, Raoufi F et al. (2001) Connective tissue growth factor is secreted through the Golgi and degraded in the endosome. Exp Cell Res 271:109-117
4. Chen P-P, Li W-J, Wang Y et al. (2007) Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2:e534
5. Chu CY, Chang CC, Prakash E et al. (2008) Connective tissue growth factor (CTGF) and cancer progression. J Biomed Sci 15:675-685
6. Cicha I, Goppelt-Struebe M (2009) Connective tissue growth factor: context-dependent functions and mechanisms of regulation. BioFactors 35:200-208
7. Gressner OA, Gressner AM (2008) Connective tissue growth factor: a fibrogenic master switch in fibrotic liver diseases. Liver Int 28:1065-1079
8. Guha M, Xu Z-G, Tung D et al. (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21:3355-3368 (Pubitemid 47565554)
9. Leask A, Parapuram SK, Xu S-W et al. (2009) Connective tissue growth factor (CTGF, CCN2) gene regulation: a potent clinical bio-marker of fibroproliferative disease? J Cell Commun Signal 3:89-94
10. Mason RM (2009) Connective tissue growth factor(CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal 3:95-104
11. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA et al. (2008) CTGF inhibits BMP-7 signalling in diabetic nephropathy. J Am Soc Nephrol 19:2098-2107
12. Pannu J, Nakerakanti S, Smith E et al. (2007) Transforming growth factor-beta receptor type I-dependent fibrogenic gene program is mediated via activation of Smad1 and ERK1/2 pathways. J Biol Chem 282:10405-10413
13. Ponticos M, Holmes AM, Xu S-W et al. (2009) Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 60:2142-2155
14. Quan TH, Shao Y, He T et al. (2010) Reduced expression of connective tissue growth factor (CTGF/CCN2) mediates collagen loss in chronologically aged human skin. J Invest Dermatol 130:415-424
15. Sanchez-Lopez E, Rayego S, Rodrigues-Diez R et al. (2009) CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappa B. J Am Soc Nephrol 20:1513-1526
16. Sawai K, Mukoyama M, Mori K et al. (2007) Expression of CCN1 (CYR61) in developing, normal, and diseased human kidney. Am J Physiol Renal Physiol 293:F1363-72
17. Xie D, Yin D, Wang H-J et al. (2004) Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clin Cancer Res 10:2072-2081